Approved cancer drug may reduce kidney damage linked to nail-patella syndrome

Researchers led by Dr. Ralph Witzgall, a prof astatine the Chair of Molecular and Cellular Anatomy astatine the University of Regensburg, person deciphered a cardinal illness mechanics underlying the hereditary kidney upset nail-patella syndrome and identified a imaginable therapeutic strategy. Their findings show that an already approved cause tin importantly trim disease-causing changes. The study, which besides progressive researchers from the Technical University of Munich (TUM), was precocious published successful the diary Nature Communications.